There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neurocrine (NBIX), Stemline Therapeutics Inc (STML) and Blueprint Medicines (BPMC) with bullish sentiments.
Neurocrine (NBIX)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Neurocrine, with a price target of $105. The company’s shares opened today at $81.48.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.3% and a 51.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Allogene Therapeutics Inc.
Neurocrine has an analyst consensus of Moderate Buy, with a price target consensus of $106.10, implying a 30.2% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $127 price target.
See today’s analyst top recommended stocks >>
Stemline Therapeutics Inc (STML)
In a report released today, Boris Peaker from Cowen & Co. reiterated a Buy rating on Stemline Therapeutics Inc. The company’s shares opened today at $13.01.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.5% and a 43.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Mersana Therapeutics Inc, CytomX Therapeutics Inc, and Jounce Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stemline Therapeutics Inc with a $30.33 average price target, representing a 133.1% upside. In a report issued on March 11, Piper Jaffray also maintained a Buy rating on the stock with a $23 price target.
Blueprint Medicines (BPMC)
In a report released today, Marc Frahm from Cowen & Co. maintained a Buy rating on Blueprint Medicines. The company’s shares opened today at $83.88.
According to TipRanks.com, Frahm is a 3-star analyst with an average return of 6.6% and a 66.7% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Unum Therapeutics Inc.
The the analyst consensus on Blueprint Medicines is currently a Moderate Buy rating.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
